Efficacy and safety of Lactobacillus paracasei CNCM I-1572 and fructo- oligosaccharides in the treatment of patients with irritable bowel syndrome with constipation

The aim is to study the effect and safety of using the antispasmodic and synbiotic (Lactobacillus paracasei CNCM I-1572 in combination with fructooligosaccharides) in patients with irritable bowel syndrome with constipation.

Materials and methods — prospective randomized controlled trial of 80 patients with irritable bowel syndrome with constipation. Patients in the main group (40 people) took mebeverine hydrochloride 200 mg 2 times a day and synbiotic (5x109 CFU Lactobacillus paracasei CNCM I-1572 and 5.2 g fructooligosaccharides) during 28 days. Patients in the control group (40 people) received mebeverine hydrochloride 200 mg 2 times a day during 28 days. Before and after treatment, patients underwent the GSPS questionnaire.

Results — in control group clinical remission was achieved in 52.6% of patients. In the main group clinical remission was established in 92.3%, the increase was 39.7% (p <0.01). The relative risk of clinical remission when synbiotic included in the treatment for patients with irritable bowel syndrome with constipation is 1.75 (95% CI 1.28–2.4; p <0.01). When analyzing adverse events of the compared treatment regimens, no statistically significant differences were found (p = 0.75).

Conclusion — the results of study demonstrate a significant increase in the effectiveness of therapy in patients with irritable bowel syndrome with constipation with the combined use of antispasmodic and synbiotic.

1. Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016 Feb 18: S0016-5085(16)00222-5. https://doi.org/10.1053/j.gastro.2016.02.031

2. Ivashkin V.T., Shelygin Yu.A., Baranskaya Y. K., et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-5-76-93

3. Barbara G, Feinle-Bisset C, Ghoshal UC, et al. The Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology. 2016 Feb 18: S0016-5085(16)00219-5. https://doi.org/10.1053/j.gastro.2016.02.028

4. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009 May;136(6):1979-88. https://doi.org/10.1053/j.gastro.2009.02.074

5. Rajilić- Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011 Nov;141(5):1792-801. https://doi.org/10.1053/j.gastro.2011.07.043

6. Jalanka- Tuovinen J, Salojärvi J, Salonen A, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014 Nov;63(11):1737-45. https://doi.org/10.1136/gutjnl-2013-305994

7. Francisco Guarner, Mary Ellen Sanders, Rami Eliakim; World Gastroenterology Organization, et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics. 2017. (in Russ.)

8. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx- Orenstein AE, Brandt LJ, Quigley EM. Th e efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010 Mar;59(3):325-32. https://doi.org/10.1136/gut.2008.167270

9. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soff er EE, Spiegel BM, Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014 Oct;109(10):1547-61; quiz 1546, 1562. https://doi.org/10.1038/ajg.2014.202

10. Cremon C, Guglielmetti S, Gargari G, et al. Eff ect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United European Gastroenterol J. 2018 May;6(4):604-613. https://doi.org/10.1177/2050640617736478

11. Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998 Jan;7(1):75-83. https://doi.org/10.1023/a:1008841022998

12. Wiklund IK, Fullerton S, Hawkey CJ, et al. An irritable bowel syndrome- specific symptom questionnaire: development and validation. Scand J Gastroenterol. 2003 Sep;38(9):947-54. https://doi.org/10.1080/00365520310004209

13. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011 Aug 10;(8):CD003460. https://doi.org/10.1002/14651858.CD003460.pub3

14. Compare D, Rocco A, Coccoli P, et al. Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of postinfectious irritable bowel syndrome. BMC Gastroenterology. 2017 Apr 14;17(1):53. https://doi.org/10.1186/s12876-017-0605-x

15. Ferrario C, Taverniti V, Milani C, et al. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J Nutr. 2014 Nov;144(11):1787-96. https://doi.org/10.3945/jn.114.197723.

16. Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease - a double-blind, randomised, placebo- controlled study. Aliment Pharmacol Th er. 2013 Oct;38(7):741-51. https://doi.org/10.1111/apt.12463

17. Azpiroz F., Molne L., Mendez S., et al. Effect of Chicoryderived Inulin on Abdominal Sensations and Bowel Motor Function. J. Clin. Gastroenterol. 2017;51:619-625. https://doi.org/10.1097/MCG.0000000000000723

18. Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, Kamm MA, Sanderson JD, Knight SC, Forbes A, Stagg AJ, Whelan K, Lindsay JO. Randomised, double- blind, placebo- controlled trial of fructo- oligosaccharides in active Crohn’s disease. Gut. 2011 Jul;60(7):923-9. https://doi.org/10.1136/gut.2010.232025

19. J de Vries, Le Bourgot C, Calame W, Respondek F. Effects of β-Fructans Fiber on Bowel Function: A Systematic Review and Meta- Analysis. Nutrients. 2019 Jan 4;11(1):91. https://doi.org/10.3390/nu11010091